Viridian Therapeutics has announced encouraging topline results from its REVEAL‑1 phase 3 clinical trial evaluating ...

Kenneth Hobby, President of Cure SMA, said: “Nearly ten years ago, the approval of Spinraza marked a turning point in SMA ...

This month’s edition reimagines the NHS dichotomy as a dystopian game of Tetris - we investigate which parties might finally ...

Announcing the approval, UCB said Kygevvi is a 2g/2g powder for oral solution and represents the first therapy available in the European Union beyond supportive care. The company noted that TK2d ...

Cure Parkinson’s has announced the formation of a new evaluation panel to review applications submitted to its recent £2 ...

DNA Script has signed distribution agreements with Gencell, Bio-Medical Science (BMS) and Biostream, expanding global access ...

Positive high‑level results from the phase 3 OBERON and TITANIA trials indicate that tozorakimab achieved statistically significant and clinically meaningful reductions in the a ...

Johnson & Johnson has announced a landmark regulatory decision that will allow people living with multiple myeloma to administer the subcutaneous formulation of daratumumab themse ...

Laigo Bio has completed the second close of its seed financing round at €5.5m, bringing the total raised to €17m ...

Ondine Biomedical has announced the North American phase 3 study has reached more than 93% enrolment, bringing the company ...

Axplora has announced plans to build a 4,500sqm R&D and laboratory hub at its Farmabios site in Gropello Cairoli in Italy ...

AlzeCure Pharma has released new preclinical findings for its lead Alzheimer’s drug candidate, NeuroRestore ACD856, following a presentation at the AD/PD 2026 international conference.